OIS Retina and ARVO meetings are being held in Seattle, WashingtonBEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to ...

About AXPAXLI™ AXPAXLI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being ...

By Dean Seal Shares of Ocular Therapeutix fell after the company reported topline data for a Phase 1 trial of its diabetic retinopathy drug candidate ...

Ocular rosacea happens when the eye develops inflammation. It causes the eyes to burn, itch, and become red. Individuals who have rosacea of the skin tend to get ocular rosacea. When an individual ...

A study in the Journal of Clinical Medicine reveals that exposure to e-cigarette vapor can lead to both accidental and direct ...

Analyst Colleen M. Kusy of Robert W. Baird reiterated a Buy rating on Ocular Therapeutix (OCUL – Research Report), retaining the price ...

The conceit behind the technology essentially is our constant interaction with computer screens does our eyes no favors.

Colloquially known as moon blindness, equine recurrent uveitis (ERU) is an inflammatory ocular disease in horses, which can ...

Discover the groundbreaking patent by EyePoint Pharmaceuticals Inc for treating ocular conditions with multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists.

The data will be presented in oral session at the 2024 American Society of Gene & Cell Therapy meeting May 7-11 in Baltimore, ...

Daniel Martin speaks with Dr Anita Chan, Head & Senior Consultant, Ocular Inflammation & Immunology Department, Singapore ...

H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 11:00 a.m. ET. The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the ...